share_log

Avenue Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

Avenue Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)

美股sec公告 ·  01/02 00:00
Moomoo AI 已提取核心信息
A regulatory filing with the United States Securities and Exchange Commission (SEC) on January 2, 2024, revealed that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz collectively reported a 4.99% stake in Avenue Therapeutics, Inc. The filing, an amendment to Schedule 13G, indicates shared voting and dispositive power over 661,056 shares of the company's common stock. Sabby Management, LLC, as the investment manager of Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz, in his capacity as manager of Sabby Management, LLC, do not directly own any shares but have an indirect interest in the same number of shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avenue Therapeutics, Inc. The principal executive offices of Avenue Therapeutics are located at 1140 Avenue of the Americas, Floor 9, New York, NY 10036.
A regulatory filing with the United States Securities and Exchange Commission (SEC) on January 2, 2024, revealed that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz collectively reported a 4.99% stake in Avenue Therapeutics, Inc. The filing, an amendment to Schedule 13G, indicates shared voting and dispositive power over 661,056 shares of the company's common stock. Sabby Management, LLC, as the investment manager of Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz, in his capacity as manager of Sabby Management, LLC, do not directly own any shares but have an indirect interest in the same number of shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avenue Therapeutics, Inc. The principal executive offices of Avenue Therapeutics are located at 1140 Avenue of the Americas, Floor 9, New York, NY 10036.
2024年1月2日向美国证券交易委员会(SEC)提交的监管文件显示,Sabby波动率权证万事达基金有限公司、Sabby Management, LLC和Hal Mintz共同报告了Avenue Therapeutics, Inc.4.99%的股份。该文件是附表13G的修正案,表明了对该公司661,056股普通股的共同投票权和处置权。作为Sabby波动率权证万事达基金有限公司的投资经理的Sabby Management, LLC和作为Sabby Management, LLC经理的哈尔·明茨不直接拥有任何股份,但间接持有相同数量的股票的权益。该文件称,收购这些股份不是为了改变或影响Avenue Therapeutics, Inc.的控制权。Avenue Therapeutics的主要执行办公室位于美洲大道1140号9楼,纽约10036。
2024年1月2日向美国证券交易委员会(SEC)提交的监管文件显示,Sabby波动率权证万事达基金有限公司、Sabby Management, LLC和Hal Mintz共同报告了Avenue Therapeutics, Inc.4.99%的股份。该文件是附表13G的修正案,表明了对该公司661,056股普通股的共同投票权和处置权。作为Sabby波动率权证万事达基金有限公司的投资经理的Sabby Management, LLC和作为Sabby Management, LLC经理的哈尔·明茨不直接拥有任何股份,但间接持有相同数量的股票的权益。该文件称,收购这些股份不是为了改变或影响Avenue Therapeutics, Inc.的控制权。Avenue Therapeutics的主要执行办公室位于美洲大道1140号9楼,纽约10036。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息